<DOC>
	<DOCNO>NCT00222872</DOCNO>
	<brief_summary>The main purpose study determine safety effectiveness three week daily subcutaneous injection Parathyroid Hormone-related Protein ( 1-36 ) . Previous study indicate PTHrP skeletal 'anabolic ' bone-building effect , show increase bone mineral density postmenopausal woman osteoporosis . Safety PTHrP determine measurement blood pressure pulse , serum blood calcium level subjective symptom . Effectiveness measure change measurement blood urine marker bone turnover .</brief_summary>
	<brief_title>3-Week Parathyroid Hormone-related Protein ( PTHrP ) Dose Escalation Study Post-Menopausal Women</brief_title>
	<detailed_description>Parathyroid Hormone-related Protein ( 1-36 ) PTHrP neuroendocrine peptide share significant homology currently FDA approve anabolic agent treatment osteoporosis : parathyroid hormone ( 1-34 ) PTH . PTH , give alone , show increase lumbar spine bone mass 12-15 % 2-3 year period . Previous study indicate PTHrP may pure anabolic effect bone . Postmenopausal woman take estrogen osteoporosis receive daily subcutaneous PTHrP 3 month exhibit 4.7 % increase bone mineral density compare take placebo . There side effect associate PTHrP , despite fact dos give 20 time usual dos PTH . In another study , young healthy volunteer receive single , one-time subcutaneous dos PTHrP amount 2 mg without dose limit toxicity . This study directly compare effect placebo escalate dos PTHrP give subcutaneously postmenopausal woman three week . Each subject four outpatient visit one inpatient 24-hour visit last day . 20 woman phase I receive either placebo 500 micrograms/day PTHrP . 500 micrograms/day select low dose similar dose use previous 3 month placebo control study . In Phase II , dose PTHrP increase increment approximately 30 % successive group , i.e. , 750 , 1000 , 1250 , 1500 microgram . After first group 10 successfully receive 500 micrograms/day 21 day , increased dos give group three subject evidence dose limit toxicity ( DLT ) occur , maximum dose 1,500 microgram reach . Dose limit toxicity specify protocol comprise either one major criterion : hypotension , orthostatic hypotension , tachycardia , hypertension , hypercalcemia hypophosphatemia ; two minor criterion : flushing , nausea/vomiting , abdominal muscle cramp , dizziness/lightheadedness , palpitation , unpleasant subjective symptom . If particular dose PTHrP cause dose-limiting toxicity , immediately precede low dose define maximum safely tolerate dose . Once maximum safely tolerate dose determine , give total ten healthy subject ensure safe well tolerate . Study method include outpatient visit day 1 , 5 , 10 , 15 , in-patient visit day 21 lab collection patient examination . Blood urine safety lab consist serum ionized calcium , total calcium , creatinine , phosphorus albumin . Efficacy labs consist urine blood measurement 25-hydroxy vitamin D , 1,25 vitamin D , PTH , osteocalcin , bone specific alkaline phosphatase , procollagen peptide-1 , C-telopeptide ( CTx ) , N-telopeptide ( NTx ) , Insulin-like growth factor ( IgF ) serum free deoxypyridinoline ( DPD ) . Subject population include 48 healthy 50-75 year old postmenopausal woman Caucasian , Asian , Hispanic . African-Americans exclude study since well document African-Americans clear quantitative difference bone density sensitivity parathyroid hormone . No bone densitometry scan do study .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Women Caucasian Hispanic Asian One year past onset menopause Weigh 50 90 kilogram Taking bisphosphonates last 2 year Estrogen replacement hormone last year SERMS last year One week worth PTHrP , PTH analog PTH past year Recent nontraumatic bone fracture within last year Significant uncontrolled cardiac , vascular , renal , pulmonary , endocrine rheumatologic disease History malignancy Anemia Significant alcohol drug abuse Receiving investigational drug within past 90 day Medications interfere metabolism renal clearance study drug , oral systemic glucocorticoid &gt; 5 mg/day prednisone ( equivalent ) past year Thiazidetype diuretic Abnormal screen lab ( calcium , vit D PTH , CBC )</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>MusculoSkeletal System Diseases</keyword>
	<keyword>Hormone</keyword>
	<keyword>Postmenopausal Women</keyword>
</DOC>